Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Drug Toxicity: Risk factors

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Long-Term Outcomes of Enzyme Replacement Therapy in Indian Patients with Gaucher Disease - A Multicentric Study.

Indian journal of pediatrics·2026

Same author

Inherited Metabolic Disorders in India: Progress and Priorities.

Indian journal of pediatrics·2026

Same author

Solid Organ Transplantation in Inborn Errors of Metabolism: An Organ-Based, Practice-Oriented Review.

Indian journal of pediatrics·2026

Same author

Rifampicin population pharmacokinetics and pharmacogenomic evaluation of SLCO1B1 gene in tuberculosis patients.

The Indian journal of tuberculosis·2026

Same author

Genetic insights: proband- only exome sequencing in pediatric neurological disorders.

Journal of community genetics·2026

Same author

Increased indolamine 2,3-dioxygenase activity in people with type 2 diabetes and comorbid depression.

The National medical journal of India·2026

Search research articles

Related Experiment Video

Updated: May 22, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Statin Hepatotoxicity: Is it a Real Concern?

Pranav Sikka¹, K K Saxena, Seema Kapoor

¹Department of Pharmacology, LLRM Medical College, Meerut, Uttar Pradesh, India.

Heart Views : the Official Journal of the Gulf Heart Association

|May 9, 2012

Summary

Statins effectively treat dyslipidemia and prevent heart disease. Despite safety, fear of liver issues causes many to stop statin therapy, increasing cardiovascular risks.

Area of Science:

Cardiology
Pharmacology

Background:

Dyslipidemia is a primary risk factor for coronary heart disease.
Statins are effective and safe hypolipidemic drugs.
Physician reluctance to prescribe statins due to hepatotoxicity concerns is common, despite limited evidence.

Purpose of the Study:

To address the unwarranted fear of statin-induced hepatotoxicity.
To highlight the consequences of statin discontinuation for dyslipidemia management.
To discuss the potential benefits of statins in patients with abnormal liver function tests.

Main Methods:

Review of existing literature on statin use and liver function.
Analysis of clinical guidelines and evidence regarding statin hepatotoxicity.
Examination of cardiovascular outcomes in patients with dyslipidemia and abnormal liver tests.

Keywords:

Dyslipidemia hepatotoxicity statins

Related Experiment Videos

Last Updated: May 22, 2026

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

Main Results:

Statins are generally safe with rare instances of significant hepatotoxicity.
Discontinuation of statins due to fear of liver damage leads to uncontrolled dyslipidemia.
Evidence suggests statins may offer cardiovascular benefits even in patients with elevated liver enzymes.

Conclusions:

The fear of statin hepatotoxicity is often disproportionate to the actual risk.
Continuing statin therapy is crucial for managing dyslipidemia and preventing cardiovascular events.
Physicians should reconsider statin initiation or continuation in patients with abnormal liver tests based on current evidence.